under the Galectin Therapeutics Inc.Stock Unit Agreement • July 26th, 2022 • Galectin Therapeutics Inc • Pharmaceutical preparations
Pursuant to the terms of the Galectin Therapeutics Inc. 2019 Omnibus Equity Compensation Plan (the “Plan”), Galectin Therapeutics Inc., a Nevada corporation (the “Company”) will issue the number of shares of the Company’s common stock equal to the number of Deferred Stock Units (“DSUs”) granted in accordance with the terms set forth in this agreement (this “Agreement”). This Agreement is entered into effective as of July 25, 2022.
First Amendment to Employment Agreement by and Between Galectin Therapeutics Inc. and Joel LewisEmployment Agreement • July 26th, 2022 • Galectin Therapeutics Inc • Pharmaceutical preparations
Amendment to Deferred Stock Unit Agreement under the Galectin Therapeutics Inc.Deferred Stock Unit Agreement • July 26th, 2022 • Galectin Therapeutics Inc • Pharmaceutical preparations
The Deferred Stock Unit Agreement dated August 31, 2020 by and between Galectin Therapeutics Inc. (the “Company”) and Joel Lewis (“Grantee”) under the Company’s 2019 Omnibus Equity Compensation Plan (the “Plan”) pursuant to which 80% of the Grantee’s base salary and annual performance bonus earned during the period beginning on September 2, 2020 and ending on December 31, 2022 shall be paid in the form of DSUs (the “2020 DSU Agreement”) is hereby amended effective July 25, 2022 as set forth herein (the “Amendment”). Capitalized terms not otherwise defined herein shall have the same meaning set forth in the 2020 DSU Agreement and the Plan.
LINE OF CREDIT LETTER AGREEMENTCredit Letter Agreement • July 26th, 2022 • Galectin Therapeutics Inc • Pharmaceutical preparations • Nevada
